Kiniksa Pharma Reports Director/Officer Changes & Compensatory Info

Ticker: KNSA · Form: 8-K · Filed: 2025-04-23T00:00:00.000Z

Sentiment: neutral

Topics: corporate-governance, executive-compensation, filing

TL;DR

Kiniksa Pharma filed an 8-K detailing director/officer changes and compensation plans.

AI Summary

Kiniksa Pharmaceuticals International, plc filed an 8-K on April 23, 2025, reporting events as of April 17, 2025. The filing pertains to the departure of directors or certain officers, the election of directors, the appointment of certain officers, and compensatory arrangements for certain officers. It also includes financial statements and exhibits.

Why It Matters

This filing indicates potential shifts in the company's leadership and executive compensation structure, which could impact strategic direction and investor confidence.

Risk Assessment

Risk Level: low — The filing reports routine corporate governance and executive compensation matters, which typically carry low immediate risk.

Key Players & Entities

FAQ

What specific director or officer positions were affected by the reported changes?

The filing indicates the departure of directors or certain officers and the election/appointment of new ones, but does not specify names or exact positions in the provided text.

Are there any details on the compensatory arrangements for the officers mentioned?

The filing states that compensatory arrangements of certain officers are part of the report, but specific details are not included in the provided excerpt.

What is the significance of the 'Financial Statements and Exhibits' item in this 8-K?

This indicates that financial statements and other relevant exhibits are being filed alongside the report on director/officer changes and compensation.

When was Kiniksa Pharmaceuticals International, plc incorporated or organized?

The company was incorporated or organized in England and Wales.

What is the primary business of Kiniksa Pharmaceuticals International, plc?

The company operates in the Pharmaceutical Preparations industry, as indicated by its Standard Industrial Classification code [2834].

From the Filing

0001104659-25-038041.txt : 20250423 0001104659-25-038041.hdr.sgml : 20250423 20250423163102 ACCESSION NUMBER: 0001104659-25-038041 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 20 CONFORMED PERIOD OF REPORT: 20250417 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20250423 DATE AS OF CHANGE: 20250423 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Kiniksa Pharmaceuticals International, plc CENTRAL INDEX KEY: 0001730430 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 000000000 STATE OF INCORPORATION: X0 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38492 FILM NUMBER: 25862025 BUSINESS ADDRESS: STREET 1: 23 OLD BOND STREET, FLOOR 3 CITY: LONDON STATE: X0 ZIP: WIS 4PZ BUSINESS PHONE: 7814319100 MAIL ADDRESS: STREET 1: 23 OLD BOND STREET, FLOOR 3 CITY: LONDON STATE: X0 ZIP: WIS 4PZ FORMER COMPANY: FORMER CONFORMED NAME: Kiniksa Pharmaceuticals, Ltd. DATE OF NAME CHANGE: 20180205 8-K 1 tm2512708d1_8k.htm FORM 8-K false 0001730430 0001730430 2025-04-17 2025-04-17 iso4217:USD xbrli:shares iso4217:USD xbrli:shares       UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549   FORM  8-K   CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934   Date of Report (Date of earliest event reported): April 17, 2025   Kiniksa Pharmaceuticals International, plc (Exact name of Registrant as Specified in Its Charter)   England and Wales   001-730430   98-1795578 (State or other jurisdiction of incorporation or organization)   (Commission File Number)   (I.R.S. Employer Identification No.)   23 Old Bond Street, Floor 3 London , W1S 4PZ England , United Kingdom (Address of principal executive offices, including zip code)   ( 781 ) 431-9100 (Registrant’s telephone number, including area code)   N/A (Former Name or Former Address, if Changed Since Last Report)   Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions   ¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)   ¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)   ¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))   ¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))   Securities registered pursuant to Section 12(b) of the Act:   Title of each class   Trading Symbol(s)   Name of each exchange on which registered Class A Ordinary Shares, $0.000273235 nominal value   KNSA   The Nasdaq Stock Market LLC         (Nasdaq Global Select Market)   Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).   Emerging growth company ¨   If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ¨           Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.   On April 17, 2025, the Compensation

View on Read The Filing